GLIX1, a treatment for recurrent and progressive glioblastoma and other high-grade gliomas, has begun human testing in a Phase 1/2a clinical trial, said…
Glioma
Myosin Therapeutics has been awarded $2 million in funding to support a Phase 1/2 clinical trial testing its lead experimental cancer therapy, MT-125, in…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMXT 1501 to treat malignant…
Inovio Pharmaceuticals and Akeso have entered into a clinical trial collaboration and supply agreement to evaluate a novel immunotherapy combining INO-5412 plus cadonilimab…
A committee of the European Medicines Agency (EMA) has recommended the approval of Ipsen‘s tovorafenib for the treatment of pediatric low-grade glioma (pLGG).
An “immuno-gene” therapy that turns a virus into a cancer-fighting agent has received a fast-track designation from the U.S. Food and Drug Administration (FDA). The…
Telix Pharmaceuticals has submitted an application to European regulators seeking approval for TLX101-Px, the company’s experimental imaging agent designed to help guide treatment decisions…
Nuvation Bio expanded a trial testing its experimental therapy, safusidenib, in people with certain forms of glioma that carry an IDH1 mutation, transitioning…
A team of scientists at the University of Cincinnati Cancer Center is embarking on a series of tests to evaluate an experimental immune-modulating treatment strategy…
The majority of patients with recurrent glioblastoma remain alive following treatment with an experimental immune-modulating combination, according to a clinical trial update from Immunitybio.
Recent Posts
- First-in-human trial launches in US to test drug for hard-to-treat AML
- Hearing my mum’s prediagnosis voice boosts me as a caregiver
- High-potency chemo may hurt, not help in myeloma treatment
- Cancer vaccine may extend survival for glioblastoma patients
- Time to cut the rebirthday cake to observe my stem cell transplant